30 March 2017
Reporter: Barney Dixon

CRISPR Therapeutics snags patent

The European Patent Office has confirmed it will grant CRISPR Therapeutics’s a patent “broadly” covering gene-editing technology.

The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human or mammalian cells.

It also covers composition claims for use in any setting, including claims for use in a method of therapeutic treatment of a patient.

Dr Rodger Novak, CEO of CRISPR Therapeutics, said: “We’re very pleased with the decision by the European Patent Office recognising the broad applicability of our foundational IP, and we look forward to pursuing additional cases to grant in other jurisdictions globally.”

The European patent application (13793997) was the subject of numerous third-party observations, including from the Broad Institute, in a bid to prevent its grant.

The underlying international patent application is based on the same US priority application that has been disputed in the US on behalf of CRISPR Therapeutics co-founder Dr Emmanuelle Charpentier and the University of California and University of Vienna.

The UK IP Office has signed off on the related applications.

It has granted a UK patent to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings (2518764), and a second (2537000) to ‘chimeric’ CRISPR/Cas9 systems in which the Cas9 protein is modified to provide alternative DNA-modulating activities.

Dr Tyler Dylan-Hyde, chief legal officer at CRISPR Therapeutics, added: “We look forward to pursuing similar findings in the US under the first-to-invent system—and throughout the approximately 80 other countries our filings cover worldwide, including Europe, all of which are on a first-to-file priority system.”

The grant follows the US Patent Trial and Appeal Board’s (PTAB) ruling in February, which upheld two patents for CRISPR-Cas9 gene-editing technology because they were aimed at “distinctly patentable subject matter”.

More Europe news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
ILO ruling “vote of no confidence” for Battistelli, says CSC
07 December 2017 | Munich | Reporter: Barney Dixon
In an open letter to the EPO’s heads of delegations, the CSC said that it interpreted the ILO’s decision as a “massive vote of no confidence in the president of the EPO"
EPO president’s impartiality questioned at ILO
06 December 2017 | Geneva | Reporter: Barney Dixon
The International Labour Organisation has questioned the impartiality of EPO president Benoît Battistelli, in two tribunal decisions concerning an EPO employee, and found that there was a conflict of interest on the part of the president
EPSU calls for halt to EPO fixed-term contracts
30 November 2017 | Munich | Reporter: Barney Dixon
The European Public Service Union has penned a letter to the European Patent Office’s Administrative Council chairman, Christopher Ernst, asking the council to reject new renewable five-year fixed-term contracts
EU Commission unveils SEP plans
29 November 2017 | Brussels | Reporter: Barney Dixon
Both the App Association and IP Europe, which were previously at loggerheads over the future of SEPs in Europe, have welcomed the communication, with ACT president Morgan Reed describing the communication as a “positive outcome”
Illumina takes victory at UK High Court
23 November 2017 | London | Reporter: Barney Dixon
Illumina has secured wins at the UK High Court of Justice in two patent infringement lawsuits against Premaitha and Ariosa
SUEPO concerned over EPO 'product' targets
22 November 2017 | Munich | Reporter: Barney Dixon
The Staff Union of the European Patent Office has voiced its concerns over increasing ‘product’ targets at the European Patent Office
Mewburn Ellis opens Munich office
16 November 2017 | Munich | Reporter: Barney Dixon
Intellectual property boutique Mewburn Ellis has opened a new office in Munich, its first expansion outside of the UK